<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097951</url>
  </required_header>
  <id_info>
    <org_study_id>HT-012-01</org_study_id>
    <nct_id>NCT04097951</nct_id>
  </id_info>
  <brief_title>HDDO-1801 Intervention Trial</brief_title>
  <official_title>A Randomized, Open-label, Single-dose Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of HDDO-18011 and HDDO-18012 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, 3-period, 6-sequence, 3-way crossover study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 8, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours</time_frame>
    <description>Montelukast and Bepotastine Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours</time_frame>
    <description>Montelukast and Bepotastine Area under Curve from time zero to the last quantifiable concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours</time_frame>
    <description>Montelukast and Bepotastine Area under Curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours</time_frame>
    <description>Montelukast and Bepotastine time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24hours</time_frame>
    <description>Montelukast and Bepotastine half time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bepotastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast + Bepotastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combinations</intervention_name>
    <description>Montelukast and Bepotastine Combination</description>
    <arm_group_label>Bepotastine</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Montelukast + Bepotastine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male aged 19 years and younger than 50 years old at the time of the&#xD;
             screening&#xD;
&#xD;
          2. Those who weigh more than 50 kg and whose calculated BMI is within the 18.0-29.0 kg/m2&#xD;
             range BMI = (weight [kg])/(key [m])2&#xD;
&#xD;
          3. A person who is judged to be suitable for a test through physical examination and&#xD;
             examination according to this test plan. That is, a person who has no congenital or&#xD;
             chronic diseases and who has not had any pathological symptoms or findings within the&#xD;
             last 3 years&#xD;
&#xD;
          4. A person who is judged to be suitable for a test in accordance with this test plan (if&#xD;
             the results of a clinical laboratory test are within or outside the reference value of&#xD;
             the hospital affiliated with Inha University Medical Center, the tester determines&#xD;
             that there is no clinical significance)&#xD;
&#xD;
          5. After hearing the detailed description of this clinical trial and fully understanding&#xD;
             it, the person who agrees in writing to decide his/her participation and to comply&#xD;
             with the precautions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persons with clinical significant cardiovascular, respiratory, liver, kidney, nervous&#xD;
             system, endocrine, blood and tumor, mental illness, and urinary tract&#xD;
&#xD;
          2. Persons with gastrointestinal relationship diseases (such as gastrointestinal ulcers,&#xD;
             gastritis, gastrointestinal tract diseases, Crohn's disease, etc.) that may affect the&#xD;
             absorption of clinical trial medications, and persons with past history of&#xD;
             gastrointestinal relationship surgery (except for simple appendectomy or hernia&#xD;
             surgery)&#xD;
&#xD;
          3. Those with genetic problems such as galactose intolerance, Lapp lactase deficient or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          4. A person with a history of hypersensitivity or clinically significant hypersensitivity&#xD;
             to a drug or other drug (aspirin, antibiotics, etc.) that contains the components of&#xD;
             Montelukast and the components of Bepotastine or the same family.&#xD;
&#xD;
          5. A person who showed a clinically significant low blood pressure (hydraulic &lt; 90mmHg)&#xD;
             or high blood pressure (hydraulic ≥ 150mmHg or dilatant blood pressure ≥ 95mmHg)&#xD;
             during the screening test&#xD;
&#xD;
          6. One of the following results is displayed in a screening test:&#xD;
&#xD;
               -  AST or ALT &gt; Double the normal range limit&#xD;
&#xD;
               -  Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
               -  Ratios of sand dune (eGFR) &lt; 60mL/min/1.73m2&#xD;
&#xD;
          7. Drinking continuously (21 units/week exceeded, 1 unit = 10 g = 12.5 mL of pure&#xD;
             alcohol) or who cannot abstain from drinking during clinical trials&#xD;
&#xD;
          8. Those who smoke continuously (more than 10 days) or who cannot quit smoking during the&#xD;
             clinical trial period.&#xD;
&#xD;
          9. Those who participated in other clinical or biological equivalence tests within six&#xD;
             months prior to the date of the first medication (the last day of the medication for&#xD;
             clinical or biological equivalence tests)&#xD;
&#xD;
         10. A person who donated all blood within 60 days prior to the date of the first&#xD;
             medication, or who donated the ingredients within 30 days, or who received the blood&#xD;
             within 30 days.&#xD;
&#xD;
         11. Those who have taken any prescription or herbal medicine within 14 days prior to the&#xD;
             date of the first dose or who have taken any general medication (OTC) within 7 days&#xD;
             (however, they may participate in a clinical trial if other conditions are reasonable&#xD;
             according to the judgment of the tester.)&#xD;
&#xD;
         12. A person who has taken a medication that induces and inhibits the drug metabolic&#xD;
             enzyme, such as barbital drugs, within one month before the start of the test&#xD;
&#xD;
         13. mentally ill and drug addicts&#xD;
&#xD;
         14. A person who has been on a diet (especially grapefruit juice or its products) that can&#xD;
             affect the absorption, distribution, metabolism, and excretion of a drug within seven&#xD;
             days prior to the date of the first dose.&#xD;
&#xD;
         15. Those who do not agree to exclude the possibility of pregnancy using the medically&#xD;
             recognized contraceptives* from the date of the first administration of the clinical&#xD;
             trial drug to the date of the last clinical trial medication.&#xD;
&#xD;
             *Medically accepted contraceptives: intrauterine devices, vascular surgery, intubation&#xD;
             and block contraception (male condoms, female condoms, cervical caps, contraceptives,&#xD;
             sponges, etc.) or when using a combination of two or more blockage methods.&#xD;
&#xD;
         16. Those who are unwilling or unable to comply with diet and lifestyle guidelines&#xD;
             required for clinical testing;&#xD;
&#xD;
         17. Other clinical laboratory tests found that the tester is unfit to participate in a&#xD;
             clinical trial due to clinical abnormalities or other reasons (e.g., non-compliance&#xD;
             with instructions, non-cooperative attitude, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cho Sang Heon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Son Su Min</last_name>
    <phone>82-2-2600-7628</phone>
    <email>smson@myhdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Junggu</city>
        <state>Incheon</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

